Undisclosed Drug Candidate

About Aluda Pharmaceuticals

Aluda Pharmaceuticals is a private, preclinical-stage biotech targeting severe immune and fibrotic diseases through a novel drug discovery paradigm. The company leverages a deep understanding of cell biology and a proprietary phenotypic screening platform to identify and drug complex, holistic targets that have been overlooked by traditional and AI-driven methods. With a clear focus on severe patient populations often excluded from trials, Aluda aims to develop differentiated therapies with efficient clinical paths. The company has published peer-reviewed data on a drug candidate, indicating progress in its pipeline.

About BML, Inc.

Founded in 1968, BML has established itself as Japan's preeminent and mission-critical provider of clinical laboratory testing services, supporting hospitals, clinics, and pharmaceutical R&D. Its achievements are built on a vast, automated, and certified laboratory network that ensures rapid, reliable diagnostics nationwide. The company's strategy leverages this dominant service foundation to selectively expand into adjacent high-value areas, including biotech research and therapeutic development, aiming to capture more of the precision medicine value chain.

Therapeutic Areas